NCT04642469
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04642469 |
| Title | Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy. (MERMAID-2) |
| Acronym | MERMAID-2 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | TUR | POL | NLD | ITA | ISR | HUN | GRC | FRA | ESP | CZE | CAN | BRA | BEL | AUS | ARG |
CKB BOOST